Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

Summary: Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in the phase 3 ALSYMPCA study. ALSYMPCA was conduct...

Full description

Bibliographic Details
Main Authors: Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:EClinicalMedicine
Subjects:
Clinical outcomes
Radium-223
Metastatic castration-resistant prostate cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023001700

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023001700

Similar Items